ArticleCardiovascular diabetology2019
Association of glycemic variability with left ventricular diastolic function in type 2 diabetes mellitus.
Article in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Relation of glucose variability on mortality from any cause and cardiovascular diseases in individuals with type 2 diabetes: mediation analysis of echocardiographic parameters.BMC cardiovascular disorders · 2025Article
- Age-Related Characteristics of Diastolic Dysfunction in Type 2 Diabetes Patients.Journal of clinical medicine · 2025Article
- Association between Hemoglobin Glycation Index and In-Hospital all-cause mortality of patients with Congestive Heart Failure: a retrospective study utilizing the MIMIC-IV database.Frontiers in endocrinology · 2025Article
- Risk Factors of Subclinical Left Ventricular Systolic Dysfunction in Older Adults with Type 2 Diabetes and Preserved LVEF.Clinical interventions in aging · 2025Article
- Research Progress of Mitochondrial Dynamics and Autophagy in Diabetic Complications: New Treatment Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- IL-35 Ameliorates Myocardial Strain in Mice with T2DM-Induced Cardiac Injury: Assessment by Layer-Specific Strain.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.Diabetes, obesity & metabolism · 2024Review
- Relationship between hemoglobin glycation index and risk of hypoglycemia in type 2 diabetes with time-in-range in target.World journal of diabetes · 2024Article
- Research progress on the association between glycemic variability index derived from CGM and cardiovascular disease complications.Acta diabetologica · 2024Review
- Glycemic variability: Measurement, target, impact on complications of diabetes and does it really matter?Journal of diabetes investigation · 2024Review
- Association between glycosylated hemoglobin levels, diabetes duration, and left ventricular diastolic dysfunction in patients with type 2 diabetes and preserved ejection fraction: a cross-sectional study.Frontiers in endocrinology · 2023Article
- Associations of advanced liver fibrosis with heart failure with preserved ejection fraction in type 2 diabetic patients according to obesity and metabolic goal achievement status.Frontiers in endocrinology · 2023Article
- Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.The Journal of clinical endocrinology and metabolism · 2022Review
- Inhibition of SGLT1 Alleviates the Glycemic Variability-Induced Cardiac Fibrosis via Inhibition of Activation of Macrophage and Cardiac Fibroblasts.Molecular and cellular biology · 2022Article
- Fasting Glucose Variability as a Risk Indicator for End-Stage Kidney Disease in Patients with Diabetes: A Nationwide Population-Based Study.Journal of clinical medicine · 2021Article
- Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.Cardiovascular diabetology · 2021Observational
- Association between sarcopenic overweight and left ventricular diastolic dysfunction and remodeling in patients with type 2 diabetes.Chinese medical journal · 2021Article
- Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus.Cardiovascular diabetology · 2021Article
- Impact of type 2 diabetes mellitus on left ventricular diastolic function in patients with essential hypertension: evaluation by volume-time curve of cardiac magnetic resonance.Cardiovascular diabetology · 2021Article
- Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort.Cardiovascular diabetology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF) with preserved ejection fraction (HFpEF), usually presenting as left ventricular (LV) diastolic dysfunction. Thus, LV diastolic function should be considered a crucial marker of a preclinical form of DM-related cardiac dysfunction. However, the impact of glycemic variability (GV) on LV diastolic function in such patients remains unclear.
methodsWe studied 100 asymptomatic T2DM patients with preserved LV ejection fraction (LVEF) without coronary artery disease (age: 60 ± 14 years, female: 45%). GV was evaluated as standard deviation of blood glucose level using continuous glucose monitoring system for at least 72 consecutive hours. LV diastolic function was defined as mitral inflow E and mitral e' annular velocities (E/e'), and > 14 was determined as abnormal.
resultsE/e' in patients with high GV (≥ 35.9 mg/dL) was significantly higher than that in patients with low GV (11.3 ± 3.9 vs. 9.8 ± 2.8, p = 0.03) despite similar age, gender-distribution, and hemoglobin A1c (HbA1c). Multivariate logistic regression analysis showed that GV ≥ 35.9 mg/dL (odds ratio: 3.67; 95% confidence interval: 1.02-13.22; p < 0.05) was an independently associated factor, as was age, of E/e' > 14. In sequential logistic models for the associations of LV diastolic dysfunction, one model based on clinical variables including age, gender and hypertension was not improved by addition of HbA1c (p = 0.67) but was improved by addition of high GV (p = 0.04).
conclusionSince HFpEF is a syndrome caused by diverse agents, reducing GV may represent a potential new therapeutic strategy for the prevention of the development of HFpEF in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.